PureTech Health plc

Report Publication Announcement • Feb 16, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1446P

PureTech Health PLC

16 February 2016

PureTech Health - Notice of results

Boston, Massachusetts, February 16, 2016 - PureTech Health plc ("PureTech" or the "Company", LSE: PRTC), a cross-disciplinary healthcare company developing novel medicines to tackle fundamental healthcare needs in disruptive ways, plans to announce its financial results for the year ended 31 December 2015 on Thursday 7 April 2016.

As previously announced PureTech will also hold its first Capital Markets Meeting in London on Tuesday 10 May 2016 from 13.00-17.00 BST. The meeting will feature PureTech presenters including members of the Company's Board of Directors and management from the Company's operating business units. Please confirm if you would like to attend the Capital Markets Meeting to PureTech.Event@fticonsulting.com

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary healthcare company, developing innovative products that could improve the lives of billions of patients. PureTech has a pipeline of 12 operating companies, seven of which are "growth stage" with external validation including strategic partnerships, outside funding, proof-of-concept or peer review in prestigious scientific journals. PureTech also has a pipeline of ten "concept phase" initiatives resulting from review of more than 650 ideas annually. PureTech is focused on areas including immune and inflammatory disorders; cognitive and psychiatric disorders; diabetes and obesity; oncology; and infectious diseases, and has over 110 patents and patent applications. PureTech's leading team and board, along with an advisory network of more than 50 expert founder-scientists and advisors across multiple disciplines, gives PureTech access to potentially ground-breaking science and technological innovation. For more information, visit www.puretechhealth.com and connect with us on Twitter.

#

Enquiries:

PureTech Stephen Muniz, Executive Vice President, Legal, Finance and Operations	+1 617 456 0042
FTI Consulting (Communications adviser to PureTech) Ben Atwell Matthew Cole	+44 (0) 20 3727 1000

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORDXGDDRUBBGLU